Stay updated on Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page
- Check3 days agoChange DetectedThe page now shows a new Revision: v3.5.4 tag replacing the previous v3.5.3, indicating a minor update to the document version. This reflects metadata refresh rather than substantive changes to the study details.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe Taiwan site listing changes from Taoyuan, Taiwan, 333 to Taoyuan City, Taiwan, 333. This clarifies the city designation in the Locations list, aiding accurate site identification and search filters.SummaryDifference0.0%

- Check25 days agoChange DetectedThe page’s revision identifier was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a minor site/version update rather than a change to the underlying study information.SummaryDifference0.0%

- Check32 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This appears to be a version bump with no changes to study details or user-facing information.SummaryDifference0.0%

- Check61 days agoChange Detected- Adds hepatocellular carcinoma as a topic on the page. Introduces a Genetic and Rare Diseases Information Center resource and updates the revision to v3.5.0.SummaryDifference0.1%

- Check75 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3; no study content or page functionality were altered.SummaryDifference0.0%

Stay in the know with updates to Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.